Table 3.
Characteristics of DSA+ patients.
|
DSA+ patients n = 9 |
|
|---|---|
| CHARACTERISTICS AT TIME OF TRANSPLANTATION | |
| Recipient | |
| Age at transplantation (years) | 50.9 ± 19.5 |
| Origin of renal disease, n (%) | |
| Glomerulonephritis | 2 (22%) |
| Diabetes mellitus | 3 (33%) |
| Vascular | 1 (11%) |
| Other | 3 (33%) |
| Duration of dialysis (months) | 18.7 ± 15.2 |
| DONOR | |
| Donor age (years) | 48.4 ± 25.2 |
| Donor sex, men, n (%) | 5 (56%) |
| Deceased donor, n (%) | 9 (100%) |
| Extended criteria donor, n (%) | 4 (44%) |
| TRANSPLANTATION | |
| Number of HLA-A, B, C, DR, DQ mismatches | 7.3 ± 2.0 |
| Combined kidney-pancreas transplantation, n (%) | 2 (22%) |
| Cold ischemia time (min) | 956 ± 320 |
| Delayed graft function, n (%) | 0 |
| IMMUNOSUPPRESSION | |
| Induction therapy: | |
| Thymoglobuline, n (%) | 8 (89%) |
| Maintenance regimen: | |
| Tacrolimus, n (%) | 4 (44%) |
| Ciclosporin, n (%) | 5 (56%) |
| mTOR-Inhibitors, n (%) | 1 (11%) |
| Mycophenolate, n (%) | 8 (89%) |
| Azathioprin, n (%) | 1 (11%) |
| Prednisone, n (%) | 9 (100%) |
| CHARACTERISTICS AT TIME OF DSA DETECTION | |
| Time elapsed since transplantation (months) | 37.6 ± 57.9 |
| eGFR (ml/min/m2) | 54.1 ± 24.6 |
| Proteinuria >0.5 g/24 h, n (%) | 1 (11%) |
| Nb of DSA specificities | 1.3 ± 0.5 |
| Anti-HLA I/II/I+II | 1 (11)/8 (89)/0 |
| MFI of immunodominant DSA | 4386 ± 6342 |
| Time elapsed between DSA detection and cTfh profiling (months) | 1.9 ± 2.0 |
mTOR, mamalian target of rapamycin; eGFR, estimated glomerular filtration rate.